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Postural hypotensionAbstract Background: Patients with long standing DM undergoing surgical interventions are put
under great challenge as they may have cardiovascular and/or cardiac autonomic neuropathy
(CAN). CAN is serious, often overlooked and under diagnosed, with possible arrhythmias and
silent ischemia that threaten life.
Objectives: Assessment of CAN in long standing type 2 diabetic women undergoing major surgery.
Study design: Cross sectional study.
Patients and methods: One hundred and six type 2 diabetic women scheduled for major surgery
were assessed by the autonomic function tests. Only one hundred cases completed the study.
CAN was assessed by analyzing HR variations during three standard tests (deep breathing, lying
to standing and valsalva maneuver). Sympathetic functions were assessed by checking orthostatic
hypotension. The CAN score of each patient was analyzed. Continuous 24 hour ECG monitoring
(Holter) was done to evaluate ischemia, arrhythmia, QTc and QTd. Transthoracic Doppler echo-
cardiography, stressing on LVH, diastolic and systolic dysfunctions were carried out. Cases were
classiﬁed as mild (with only one abnormal test) or severe CAN when two or more abnormal func-
tion tests were present. Exclusion criteria include any systemic illness that can affect the study
results or the autonomic functions, smoking and HTN.
Results: CAN was detected in 70% of the studied cases, and 70% were severe CAN. Postural
hypotension was detected in 34% of the studied cases. QTc prolongation and QT dispersion were
frequent. ECG and Doppler echocardiography changes of LVH were more prevalent among
patients with CAN. Diabetics with CAN were signiﬁcantly older had longer duration of DM
64 W. Refaieand higher HbA1-c, higher pulse pressure, triglyceride, uric acid and urinary albumin excretion rate.
They also had signiﬁcant increased LVM index, diastolic dysfunction and myocardial ischemia.
Conclusion: Middle aged women with long standing diabetes are vulnerable to CAN with postural
hypotension and prolonged QTc intervals, QT dispersion, and increased LVMI and myocardial
ischemia. Identiﬁcation of CAN is crucial to exercise prevention against hazards of CV insults dur-
ing stressful situation as surgery.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Autonomic neuropathy, although not rare, is one of the most
insidious complications of diabetes mellitus (DM) especially if
long standing and poorly controlled. Cardiac autonomic neu-
ropathy (CAN) is often overlooked both in diagnosis and
treatment simply because there is no widely accepted single ap-
proach to its diagnosis.1 CAN embraces exercise intolerance,
intraoperative cardiovascular liability, orthostatic syndromes
and silent myocardial ischemia.2–4 These clinical manifesta-
tions can result in life threatening outcomes which unquestion-
ably associate the presence of CAN with the increased risk of
CV morbidity and mortality in DM.
In the Eurodiab prospective study on type one diabetes
mellitus CAN was among the strongest risk markers of future
total and CV mortality exceeding the effect of traditional risk
factors as age, obesity, hypertension, dyslipidemia, inﬂamma-
tory and prothrombotic emerging cardiac risk factors..4,5 In
a Meta analysis of 12 published studies Vinik et al.6 reported
a constant association between CAN and silent myocardial
ischemia and in the DIAD study, on type 2 DM CAN was a
stronger predictor of silent ischemia and subsequent cardiac
events.7
QTc interval and QTd have been considered as a marker of
cardiac autonomic dysfunction and have been demonstrated as
an independent predictor of CV mortality and all cause mor-
tality risk in type 2 DM patients.4 Combined abnormality in
HRV and QT index was a strong predictor of mortality inde-
pendent of conventional risk factor.8,9
Action to Control Cardiovascular Risk in Diabetes (AC-
CORD trial) in the presence of CAN at baseline was an inde-
pendent contributor to the higher CV mortality risk in both
the intensive and standard glycemic arm treatment. Individuals
with baseline CAN were two times more likely to die compared
with individuals without CAN.10,11 A lot of attention has been
given to the CV aspect of autonomic dysfunction especially
with the view regarding very tight glycemic control with in-
creased mortality. ACCORD trial12 attributed increased mor-
tality to hypoglycemia induced arrhythmias.1
There is no widely accepted single approach to the diagno-
sis of CAN, however during the 1970s Ewing et al.,13 advised a
number of simple bedside tests of short term RR difference to
detect CAN including changes in RR with deep breathing, RR
response to standing which induces reﬂex tachycardia followed
by bradycardia and Valsalva ratio which evaluates cardiovagal
function in response to a standard increase in intrathorathic
pressure. HRV is a physiological phenomenon that reﬂects
the inﬂuence of autonomic nervous system on the heart
work.13 HRV can be deﬁned as the phenomenon of oscillation
in the intervals between the consecutive heart beats as well as
the oscillation between consecutive instantaneous heart
rates.13bOrthostatic hypotension with its many troublesome symp-
toms ranging from light headedness to near syncope that
may be associated with poor quality of life with fall in systolic
BPP 20 mmHg andP10 mmHg in diastolic BP during 3 min-
utes of standing and resolving with sitting or lying down is
characteristic of CAN.14,15
The clinical symptoms of CAN may be late, however sub-
clinical CAN manifest as changes in HRV may be detected
within one year of diagnosis of type 2 DM.16
Pop Bussi and coworkers,17 reported that the prevalence of
CAN ranges from as low as 2.5% (DCCT) to as high as 90%
in long standing DM and should be instituted at diagnosis of
type 2 DM and after 5 years of diagnosis of type 1.18 Vinik
and Ziegler,19 reported that, the detection of CAN is a must
before exposing patients with long standing DM to stressful
situation and also before planning exercises. Diabetics must
be tested with a cardiac stress test before undergoing an exer-
cise program. Patients with CAN need to rely on their per-
ceived exertion and not heart rate to avoid the hazardous
levels of exercise intensity.19
2. Aims
Assessment of cardiac autonomic dysfunction in middle aged
women with long standing type 2 DM who are going to be ex-
posed to stress in the form of major surgery.
3. Design
Cross sectional study.
4. Subjects and methods
The studied cases included one hundred and six women. They
are known to be diabetics and were under oral hypoglycemic
agents (70 cases) and 30 cases were under combined insulin
and sulfonylurea. All were receiving metformin 1.7 gm/day.
Their age ranged from 40 to 60 years (mean 52.4 ± 3.7 years).
The mean duration of DM was 10 ± 2 years ranging from (6–
14 years). BMI ranging from 25.1 to 29.2 (mean 27.1 ± 1.1).
They were scheduled for hysterectomies and/or classical repair.
All medications that can affect the result of the autonomic
functions (anticholinergic agents, adrenergic antagonists, vaso-
constrictive agents) were withhold during and one week pre-
ceding the clinical assessment of autonomic functions.
Examinations were undertaken in the morning at least 2 h
after a light breakfast and no caffeine was allowed. The pa-
tients were asked about symptoms suggestive of autonomic
neuropathy, postural hypotension and myocardial ischemia.
Diabetic complications as retinopathy were checked and
peripheral neuropathy, and sudomotor neuropathy were
Assessment of cardiac autonomic neuropathy in long standing type 2 diabetic women 65stressed upon. Clinical examination, with stress on heart rate,
SBP, DBP, pulse pressure was undertaken, Testing of auto-
nomic parasympathetic dysfunction was assessed by HRV test-
ing of Ewing’s methodology 198013 (heart rate ECG RR
intervals on resting, standing, deep respiration and valsalva).13
Heart rate variability was calculated from the RR interval
using short continuous ECG recording. Continuous 24 hours
ECG monitoring (Holter) was also used to evaluate ischemia,
arrhythmia, QTc intervals QT/
p
R-R (Bazetts formula) and
QTd (the difference between the longest and the shortest R
waves). The resting 12 lead ECG was also undertaken to show
beside HRV evidence of LVH QRS amplitude >35 ms in peri-
cordial leads (Rv 1,2 + Sv 5,6 > 35) and/or ischemia. Prolon-
gation of the QTc interval >460 ms, ﬂattening of the T wave
and ST segment depression were considered as evidence of
HRV and myocardial ischemia.
Testing for sympathetic dysfunction by postural hypoten-
sion in supine and after standing for 3 min was undertaken
with the standard mercury sphygmomanometer. The measure-
ment in the supine position was taken after at least 15 min of
rest and measurement in standing position was taken at the
third minute of standing.14
Transthoracic Doppler echocardiography stressing on
LVMI Devereux formula = 0.8 · 1.04 · LV mass {(LVIDD+
PWTD+ IVSTD)3LVIDD3} + 0.6 g, diastolic dysfunction
utilizing the E/A ratio and for systolic dysfunction the EF and
ﬁbrous shortening was carried out.
Biochemical studies were undertaken stressing on blood
glucose, fasting and post 75 g glucose challenge together with
HbA1-c, serum creatinine, plasma cholesterol, triglyceride, ser-
um uric acid and 24 h urine albumin excretion.
The prevalence and the severity of CAN was assessed
according to the number of autonomic function tests of Ew-
ing’s methodology, and the CAN score in each patient was
analyzed.13,19
Subclinical CAN cases or mild CAN with only one abnor-
mal function test were compared to severe CAN cases (2 or 3
abnormal autonomic function).
The study protocol was approved by the scientiﬁc commit-
tee of Mansoura Faculty of Medicine and informed consents
were obtained.
4.1. Exclusion criteria
Systemic illness that can affect the study results or the auto-
nomic functions as CHF, CAD, arrhythmia, renal, hepatic
impairment, HCV infection, severe anemia, thyroid dysfunc-
tion, smoking, concomitant treatment with anticholinergic
agents, adrenergic antagonists, and vasoconstrictive agents
that can affect the results of autonomic function test and
patients with BPP 140/90 mmHg on two occasions 2 weeks
apart were not included.5. Statistical analysis
Was performed by using the statistical package for social sci-
ence program (SPSS) version ‘‘16’’. The qualitative data were
presented as frequency and percentages. The quantitative data
were examined by using the Kalmogrov–Smirnov test to test
for normal distribution of the data and when parametric, ex-
pressed as mean and standard deviation. Student t test wasused, to test for difference in normally distributed quantitative
data between the two groups. Mann–Whitney–l test was used
for comparison between two groups when data are not nor-
mally distributed. Signiﬁcance was considered when P value
was less than 0.05.6. Results
The prevalence of CAN as assessed by signs of autonomic neu-
ropathy including HRV tests E/I ratio (expiration to inspira-
tion) standing to lying ﬂat, valsalva maneuver, was 70% (20
cases with single HRV testing, 26 cases with 3 HRV testing,
and 24 cases with moderate CAN where two HRV tests were
present).
Postural hypotension was detected in 34% of the studied
cases and mean pulse pressure was signiﬁcantly elevated in dia-
betics with CAN when compared to those without CAN
(P< 0.01).
Prolonged QTc (>460 ms) in 38% of the whole studied
cases and 60% of the CAN cases had signiﬁcantly increased
QTd (>10 ms) when compared to the non CAN group as evi-
dent by the continuous 24 h ECG Holter monitoring.
Women with DM and CAN were signiﬁcantly older with a
signiﬁcant longer duration of uncontrolled DM with insigniﬁ-
cant differences in BMI.
Urogenital symptoms were signiﬁcantly evident in the CAN
group (P< 0.04) together with peripheral neuritis detected by
monoﬁlament with feet dryness (P< 0.01). SBP, DBP and the
mean pulse pressure were signiﬁcantly higher in the CAN
group (P< 0.001).
History suggestive of stable angina and/or acute coronary
syndrome showed insigniﬁcant differences.
Signiﬁcant higher BG level and HbA1-c in the CAN group
was observed with signiﬁcant hypertriglyceridemia and eleva-
tion in uric acid in the CAN group. The urinary albumin excre-
tion in the CAN group was signiﬁcantly elevated than in the
non CAN group (P< 0.01).Comparing the studied parame-
ters in relation to the severity of CAN showed insigniﬁcant
changes apart from signiﬁcant older age, more postural hypo-
tension, HbA1-c, serum creatinine, urine albumin excretion
and QTc. Signs of LVH and QTd revealed a borderline signif-
icant increase in severe CAN cases.7. Discussion
It was aimed in the present study to evaluate the CAN in mid-
dle aged women with long standing diabetes scheduled for
stressful situation in the form of major surgery (hysterectomies
and/or classical repair). Detection of CAN preoperatively is
necessary as such patients are vulnerable to perioperatve car-
diovascular instability with a greater decline in heart rate
and BP during induction of anesthesia and more severe
hypothermia.19,3
In the present study, the prevalence of CAN as detected by
Ewings et al 1970s proposals of heart rate variability tests (Ew-
ings et al. 1980) was high (70%). As the determination of CAN
is usually based on a battery of autonomic function tests and
as the proceeding from a consensus conference,20 recom-
mended three tests. In the present study, the golden standard
clinical autonomic testing21 was followed.
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ing to the way of detecting HRV state being the highest (30%)
by the valsalva maneuver procedure and the lowest (20%) by
the diminished expiration to inspiration ratio (E/I ratio) and
by standing to laying ﬂat. The scoring of CAN was calculated,
where more than one fourth (26%) had P3 positive tests and
24% hadP2 positive. This is in accordance with Katsilambo-
rus et al.,1 that autonomic neuropathy and CAN are not at all
rare, but are often overlooked.
The prevalence of CAN ranged from as low as 2.5%
(DCCT)17 to as high as 90% in long standing DM and in
69% of treatment induced neuropathy.22 In the present study
the valsalva ratio was 30% and E/I ratio was 20%. Our results
are not in accordance with England and coworkers,23 who
found that HRV with deep breathing is the most widely used
test of cardiovagal parasympathetic dysfunction. Cardiovascu-
lar sympathetic function was assessed by measuring the BP re-
sponse to orthostatic changes24,25 and was detected in 34% of
the studied cases.
The prevalence of CAN in the present study is higher than
that of Zeigler et al.,26 who by using HRV tests found that
34.3% of type 2 DM patients had abnormal functions. Similar
to Cabezas–Cerrato et al.,27 the HR response to deep breath-
ing in the present study was the least evident among the stud-
ied cases.
In the present study, the studied cases were all females this
could avoid gender related difference in biochemical and
hematological values.28,29 CAN was more prevalent in diabet-
ics of longer duration, older age, those with more pulse pres-
sure, higher serum triglycerides and with more elevatedTable 1 Prevalence of CAN by the different assessment tests.
Method
HRV: ﬂE/I ratio with deep breathing (61.1)
HRV:ﬂStanding to lying ﬂat
HRV:Valsalva maneuver
Postural hypotension
QTc prolongation > 460 mm
QTd > 10 ms
Table 2 Clinical ﬁndings in diabetes with CAN versus diabetics wi
Present
No. 70
Age (years) 54.4 ±
BMI(Kg/m2) 26.3 ±
Duration of DM 9.9 ± 3
Resting heart rate 94 ± 8
Postural hypotension 34cases
Symptoms suggestive of CAN in other systems
-gastrointestinal 4 cases
-Urogenital 20 case
-Sudomotor (dry feet) 8 cases
Peripheral neuritis 56 case
Dry skin 42 case
SBP 130 ±
DBP 80 ± 4
Mean pulse pressure 50.5 ±
Angina 0HbA1-c. Kodama et al.,30 in a meta analysis study described
the association of pulse pressure as a cardiovascular risk in
DM. Makimattila et al.,31 found that poor glycemic control
was the most important independent predictor of decrease in
all measures of absolute power of HRV.
Our ﬁndings are in agreement with those of Voulgari
et al.,21 who mentioned that in type 2 DM patients, CAN
has been independently associated with elevated BP, hypergly-
cemia, longer diabetes duration, dyslipidemia and the presence
of microvascular complications.32,21 Katsilambors et al.,1 re-
ported the association of high serum uric acid level and sundo-
motor dysfunction in patients with type 2 DM and CAN. In
the present study similarly serum uric acid showed higher
but insigniﬁcant differences (See Table 1).
In the present study (Table 2) the urogenital symptoms
were signiﬁcantly more frequent in diabetics with CAN. This
is not in line with Gibons and Freeman33 who reported that
symptoms of orthostatic intolerance and gastrointestinal dys-
function, urinary frequency, nocturia and anhydrosis were
more frequent in diabetics with CAN.
Peripheral neuropathy was present in 80% of the examined
cases. This is in agreement with Vinik and Ziegler,34 and Gan-
dhi et al.,35 who found that combined indices of autonomic
and peripheral neurological dysfunction is associated with ear-
lier CAN detection.36,37 In the EURODIAB24 prospective
complication study peripheral and autonomic neuropathy
were among the strongest risk markers exceeding the effects
of the traditional risk factors (See Tables 3–5).
Orthostatic hypotension was demonstrated in 34% of the
whole studied cases and in 60% of the CAN group.No of cases Percentage (%)
20 20
20 20
30 30
34 34
38 38
42 42
thout CAN.
CAN Absent CAN P
cases% No. 30 cases%
6.1 48.6 ± 4.1 <0.001
1.2 26 ± 1.1 0.226
.1 6.3 ± 1.1 <0.001
92 ± 6 0.172
48.57% 2 cases 6.66% <0.001
7.1% 1 case 3.3% 0.88
s 28.6% 3 cases 10% 0.044
11.4% 3 cases 10% 0.84
s 80% 6 cases 20% <0.001
s 60% 3 cases 10% <0.001
5 120 ± 5 <0.001
75 ± 5 <0.001
3 45.5 ± 2 <0.001
0 1
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fatigability, faintness on standing was very frequent (60%).
However no reported cases of clear or near syncope were re-
ported. Orthostatic hypotension in CAN is secondary to effer-
ent sympathetic vasomotor denervation causing reduced
vasoconstriction of the splanchinic and other peripheral bed.20
In the present study the resting heart rate in the CAN group
was around 100 bpm but was insigniﬁcantly rapid than in theTable 3 Biochemical ﬁndings in Diabetes with CAN versus diabeti
Present CAN
No. 70 cases
FBG mgm/dl 180 ± 10
Post 75 gm glucose challenge mgm/dl 310 ± 9
HbA1-c% 10.2 ± 1.1
S. cholesterol mgm/dl 198 ± 16
S. Triglyceride mgm/dl 189 ± 11
S. Uric acid mgm% 6.9 ± 1.2
S. Creatinine mgm 1.3 ± 0.2
Urine 24 h alb excretion mg/24 h 130 ± 1.2
HB gm% 10.9 ± 0.2
S. TSH 1.8 ± 0.4
Table 4 ECG ﬁndings and transthoracic Doppler Echocardiograph
Present CAN
No. 70 cases%
QTc intervalP 460 ms 42 cases 60%
QTdP 10 ms 42 cases 60%
Flattened T wave 28 cases 40%
ST segment depression 28 cases 40%
Evidence of LVH 28 cases 40%
LVM indexP 126 gm/ m2 50 cases 70.1%
E/A ratio < 1 40 cases 57.1%
EF> 60% 60 cases 85.7%
Table 5 Clinical, biochemical and ECG ﬁndings of cases with subc
Mild CAN
18 cases
Age (years) 56.9 ± 2.1
BMI(Kg/ m2) 26.6 ± 1.2
WC 95 ± 3.5
Duration Of DM 9.8 ± 3.1
SBP 138 ± 5
DBP 88 ± 4
Mean pulse pressure 74.5 ± 4
Resting Heart Rate 96 ± 8
Postural hypotension 2cases 11.1%
HbA1-c 8.9 ± 1.1
S. cholesterol mgm/dl 205 ± 10.2
S. Triglyceride mgm/dl 199 ± 8.1
S. Uric acid mgm % 6.6 ± 1.2
S. Creatinine mgm 1.2 ± 0.2
Urine 24 h alb excretion 190 ± 1.2
QTc interval 448.1 ± 9.9
QTd > 10 ms 6 cases 33.3%
Twave – duration 1.6 ± 0.1
-Amplitude 2.9 ± 0.5
Evidence of LVH 6 cases 33.3%non CAN group. This is in line with Pop-Bussi17 who stated
that increased resting heart rate is not a reliable diagnostic cri-
terion for CAN in the absence of other signs.
In the present study QTc prolongation and the more preva-
lent QT dispersion, are in agreement with Voulgari et al.4 QTc
interval was considered as a marker of cardiac autonomic
dysfunction and is signiﬁcantly associated with LVH.4 The
increase in the number of the abnormal CAN function testscs without CAN.
Absent CAN P
No. 30 cases
138.6 ± 4.1 <0.001
260 ± 1.1 <0.001
9.2 ± 1.1 <0.001
193 ± 30 0.39
180 ± 8.0 <0.001
6.1 ± 1.9 0.035
1.2 ± 0.3 0.097
105 ± 1.1 <0.001
10.8 ± 0.3 0.097
1.7 ± 0.5 0.334
y in Diabetes with CAN versus diabetics without CAN.
Absent CAN P
No. 30 cases%
10 cases 33.3% 0.01
10 cases 33.3% 0.01
10 cases 33.3% 0.531
9 cases 30% 0.344
3 cases 10% 0.003
10 cases 33.3% <0.001
10 cases 33.3% 0.029
26 cases 86.6% 0.599
linical mild CAN versus severe CAN cases.
Moderate to severe CAN P
52 cases
55.1 ± 2.5 0.003
27.2 ± 1.1 0.066
96 ± 4.1 0.321
9.9 ± 1.1 0.893
140 ± 5 0.148
90 ± 5 0.091
75.5 ± 3 0.335
99 ± 6 0.149
32 cases 64% <0.001
10.3 ± 1.1 <0.001
210 ± 8.9 0.068
201 ± 7.1 0.355
7.1 ± 2.2 0.233
1.6 ± 0.8 0.001
200 ± 1.2 <0.001
460.1 ± 10.1 <0.001
30 cases 57.7% 0.076
1.5 ± 0.8 0.38
3 ± 0.11 0.402
30 cases 57.7% 0.076
68 W. Refaieincreases the risk more.38 Pappachen et al.39 concluded that
QTc interval can be used to diagnose CAN and the combined
abnormality of HRV and QT index was a strong predictor of
mortality independent of conventional risk factors.40,41
Prolongation of QTc interval was detected in 60% of the
CAN cases with elevation of R wave amplitude with decreased
HRV. This coincides with the ﬁnding of Lombardi.42 LVH was
signiﬁcantly manifest in the CAN group in comparison to the
non CAN group.
In the present study QTc interval prolongation (>440 ms)
has been associated with increased age, SBP, DBP, central
obesity and severity of autonomic neuropathy. This is in
accordance with the ﬁnding of Ewing et al.43 and Veglio et al.44
Comparing mild CAN cases and severe CAN cases revealed
some clinical, biochemical, electrocardiographic and echocar-
diographic signiﬁcant differences including; older age, more
postural hypotension, elevated HbA1-c, serum creatinine,
24 h urine albumin excretion and more frequent QTc prolon-
gation which may impose more cardiovascular risk.8. Conclusion
CAN in women with type 2 DM are common. Detection of
CAN irrespective of its scoring in patient with DM is of impor-
tance and can help to exercise more precautions during their
diabetic management. Special clinics for cardiac autonomic
neuropathy may be warranted.References
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